Amgen, Inc. (AMGN) Stock Price Today
Aura AI Summary
Key Stats
- $195.01BMARKET_CAP
- -VOLUME
- HealthSECTOR
- $388.16FIFTY_TWO_WEEK_HIGH
- $271.18FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $240.30BENTERPRISE_VALUE
- 2.79%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $388.16, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
Law firm investigates fiduciary breaches at First Solar, Hub Group, Navan, and ZoomInfo for misleading shareholders.
Grabar Law Office is investigating claims against officers and directors of First Solar, Hub Group, Navan, and ZoomInfo for alleged breaches of fiduciary duties and securities fraud. The investigations focus on misleading statements and omissions rel...
Bending Spoons IPO spikes then drops amid concerns over profits and transparency
Bending Spoons S.p.A. went public at $29, surged to $40.50 on debut, but then fell over 11% the next day. Despite serving 500 million monthly users and having $2.61 billion in pro forma revenue, the company posted only $22.4 million in profit last ye...
Lawsuit alleges Five9 insiders misled shareholders on business performance and bookings.
Kuehn Law is investigating Five9, Inc. officers and directors for allegedly misleading shareholders by misrepresenting the company's business strength and bookings. The lawsuit claims Five9 overstated its new business growth and failed to disclose ch...